Physician profile
Sunil Cherry
NPI 1659559763
$10,783.52
in general payments reported to CMS, 2019-2025
47 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,136 · 2020: $2,274 · 2021: $1,897 · 2022: $1,574 · 2023: $1,576 · 2024: $1,058 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,902.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,060.30 | 2019-2025 | Nuplazid |
| Abbvie INC. | $956.52 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $850.29 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Ucb, INC. | $706.31 | 2019-2025 | Briviact, Fintepla |
| Sunovion Pharmaceuticals INC. | $700.37 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $605.31 | 2022-2025 | |
| Amgen INC. | $587.34 | 2019-2023 | Aimovig |
| Amneal Pharmaceuticals LLC | $585.95 | 2019-2025 | Rytary, Crexont, Lyvispah |
| Sk Life Science, INC. | $522.41 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $424.70 | 2019-2022 | |
| Biogen, INC. | $354.34 | 2019-2023 | Plegridy, Vumerity |
| Novartis Pharmaceuticals Corporation | $306.78 | 2019-2025 | |
| Greenwich Biosciences, INC. | $292.45 | 2019-2021 | |
| Emd Serono, INC. | $282.46 | 2019-2020 | |
| Lilly USA, LLC | $260.76 | 2019-2021 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $247.70 | 2023-2025 | Rexulti, Nuedexta |
| Eisai INC. | $202.62 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $189.86 | 2022-2025 | Ingrezza, Ongentys |
| Biohaven Pharmaceuticals, INC. | $177.71 | 2020-2021 | |
| Ceribell, INC. | $141.77 | 2025 | Pocket Eeg Device |
| Kyowa Kirin, INC. | $136.83 | 2020-2021 | |
| Pfizer INC. | $136.75 | 2019-2024 | |
| Genzyme Corporation | $118.06 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $105.72 | 2020-2021 | |
| Aquestive Therapeutics, INC. | $78.04 | 2020-2021 | |
| Ge Healthcare | $77.21 | 2019-2024 | |
| Abbott Laboratories | $66.07 | 2021-2025 | Freestyle Libre 3 |
| Lundbeck LLC | $65.92 | 2020-2025 | Rexulti, Vyepti |
| Biohaven Pharmaceutical Holding Company Ltd. | $48.63 | 2022 | |
| Mdd US Operations, LLC | $46.05 | 2019-2022 | |
| Chiesi USA, INC. | $42.34 | 2022 | |
| Medtronic, INC. | $41.98 | 2024 | Linq II |
| Medtronic USA, INC. | $39.16 | 2019 | |
| Csl Behring | $36.18 | 2020-2021 | |
| Acorda Therapeutics, INC | $34.07 | 2019 | |
| Neurelis, INC. | $33.78 | 2020 | |
| Argenx US, INC. | $30.84 | 2022-2023 | Vyvgart |
| Allergan, INC. | $30.05 | 2020-2022 | |
| Impel Pharmaceuticals INC. | $22.83 | 2023 | Trudhesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.50 | 2025 | Caplyta |
| Boston Scientific Corporation | $18.95 | 2020 | |
| Livanova USA, INC. | $18.60 | 2019 | |
| Insightec,INC | $17.97 | 2023 | Exablate |
| Avion Pharmaceuticals | $17.92 | 2022 | |
| Ani Pharmaceuticals, INC. | $16.08 | 2023 | Purified Cortrophin Gel |
| Strongbridge US INC. | $15.36 | 2020 | |
| Avanir Pharmaceuticals, INC. | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.